Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

CMOP±R

Phase 2Small molecule

TThe First Affiliated Hospital of Soochow University

CMOP±R is one of 2 small molecule programs targeting NHL. It is currently in Phase 2.

1

Indications

1

Total Trials

1

Active Trials

1

Competitors

Pipeline

Status by Indication[3][1]

Indication

NHLRecruiting

NHLPhase 2

Recruiting

Competition

Competitive Landscape

1 competitor in NHL

#DrugCompanyPhaseTrials

Tecentriq

CMOP±R

TThe First Affiliated Hospital of Soochow University

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 2Recruiting

NHL

NCT06486337

Clinical

Trials by Indication[1]

NHL1 trial

A Single-arm, Multi-center, Prospective Clinical Study of Mitoxantrone Hydrochloride Liposome Injection-based CMOP±R Regimen in the Treatment of Newly Diagnosed Non-Hodgkin's Lymphoma

Recruiting·TThe First Affiliated Hospital of Soochow University·Phase 2·NCT06486337·197 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for CMOP±R. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — CMOP±R compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for CMOP±R. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — The First Affiliated Hospital of Soochow University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: TThe First Affiliated Hospital of Soochow University

Related News